Survival for HCV Cirrhosis, SVR Same As General Population

This article originally appeared here.
Share this content:
Survival for HCV Cirrhosis, SVR Same As General Population
Survival for HCV Cirrhosis, SVR Same As General Population

TUESDAY, May 10, 2016 (HealthDay News) -- For patients with compensated hepatitis C virus (HCV) cirrhosis, those who achieve sustained virologic response (SVR) on an interferon-based (IFN) regimen have survival comparable to that of the general population, according to research published online April 5 in the Journal of Hepatology.

Savino Bruno, M.D., from Humanitas University and IRCCS Istituto Clinico Humanitas in Rozzano, Italy, and colleagues evaluated prospective surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis. Participants included patients who achieved SVR on an IFN regimen and non-SVR, untreated, and decompensated patients.

The researchers found that 28 of the 181 patients died during a median follow-up of 9.6 years. For the whole series, the 10- and 20-year overall survival rates were 90.9 and 62.9 percent, respectively. In the corresponding age- and sex-matched general population, the number of expected deaths was 28.1 corresponding to a standardized mortality ratio (SMR) of 1.00; the SMRs were 3.85, 3.01, and 6.70 for non-SVR patients, untreated, and decompensated patients, respectively.

"Patients with compensated HCV cirrhosis achieving SVR by IFN obtain a main benefit levelling their survival curve to that of the general population," the authors write. "Wider applicability of IFN-free regimens will possibly make this achievement more generalizable."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC Concerned About Falling Flu Vaccination Rates

CDC Concerned About Falling Flu Vaccination Rates

Decline among vulnerable older adults is of particular concern

One in Five With Non-Valvular A-Fib Receiving Digoxin

One in Five With Non-Valvular A-Fib Receiving Digoxin

Indication for digoxin use was considered inappropriate in 59.8 percent in Turkish cohort

Rapid, Successful Response to ART for Many Patients With HIV

Rapid, Successful Response to ART for Many Patients ...

Factors associated with virological success include having undetectable viral load, use of three drugs

is free, fast, and customized just for you!

Already a member?

Sign In Now »